Renal Cell Carcinoma

Novel clinical trials are currently assessing the combination of VEGF-targeted agents and immune checkpoint inhibitors as frontline therapies for patients with metastatic renal cell carcinoma (RCC).

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.

Combining a selective class I oral histone deactylase (HDAC) inhibitor with high-dose interleukin (IL)-2 may boost the latter's antitumor effect in renal cell carcinoma (RCC).

Nivolumab shows consistent survival benefit across subgroups as a second-line treatment for renal cell carcinoma (RCC), according to data from an analysis of the phase III CheckMate-025 trial.

In a comparison study, cabozantinib significantly boosted progression-free survival (PFS) against everolimus in patients with renal cell carcinoma (RCC) regardless of metastases degree, type, number of prior treatments, or patient risk status.

The programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors "are going to disrupt the current treatment paradigm and will likely be the backbone of combination therapy," said Hans J. Hammers, MD, PhD.

The FDA has received a new drug application for cabozantinib (Cometriq) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

The FDA has approved nivolumab (Opdivo) as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

The treatment paradigm for renal cell carcinoma (RCC) could undergo major changes in the future due to several novel therapies in the works for regulatory approval and checkpoint inhibitors, vaccines, recombinant T-cell receptors, and bi-specific T-cell engagers.

The PD-1 inhibitor nivolumab (Opdivo) has gained a priority review status from the FDA as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogenic therapy.

Dr. Robert Figlin talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.

Unspecific immunotherapy with interleukin-2 (IL-2) and interferon-alpha was regarded as the first effective therapy in patients with RCC, leading to remarkable clinical benefit in attaining durable complete responses.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director, Urologic Oncology, University of Chicago Medicine, discusses the potential of immunotherapy on the treatment of renal cell carcinoma.

The risk of death for patients with advanced renal cell carcinoma (RCC) was reduced by 27% with nivolumab (Opdivo) versus everolimus (Afinitor), and overall survival (OS) was improved by 5.4 months.

The PD-1 inhibitor immunotherapy Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Cabozantinib (Cometriq) was given a breakthrough therapy designation by the FDA for the treatment of patients who have advanced renal cell carcinoma (RCC), following one prior therapy.

Lenvatinib (Lenvima) was recently granted a breakthrough therapy designation by the FDA as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received a VEGF-targeted therapy.

An independent panel has halted the phase III CheckMate-025 trial after determining that nivolumab (Opdivo) improved overall survival versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.

Sunitinib treatment is associated with a significantly increased risk of all-grade and high-grade hypertension.

Lenvatinib alone and in combination with everolimus significantly improved progression-free survival compared with everolimus alone in a phase II study of patients with metastatic renal cell carcinoma.

Treatment with the PD-1 inhibitor nivolumab was active and tolerable across three doses for patients with metastatic renal cell carcinoma.

Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.

Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).

Growth in healthcare spending in the United States continues to outpace growth in European countries that enjoy a similar standard of living.

Treatment with 2 angiogenesis-targeting drugs led to objective responses in a fourth of patients with advanced renal cell carcinoma (RCC), results of a dose-finding study showed.